The interaction between inflammation, urinary symptoms and erectile dysfunction in early-stage prostate cancer treated with brachytherapy.
erectile dysfunction
inflammation
neutrophil-lymphocyte ratio
prostate cancer
Journal
Andrologia
ISSN: 1439-0272
Titre abrégé: Andrologia
Pays: Germany
ID NLM: 0423506
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
12
03
2021
received:
05
02
2021
accepted:
23
03
2021
pubmed:
15
4
2021
medline:
22
6
2021
entrez:
14
4
2021
Statut:
ppublish
Résumé
Erectile function has been shown to decline as a function of increasing peripheral blood inflammatory markers, namely the neutrophil-to-lymphocyte ratio (NLR). We evaluated if the association between NLR and erectile dysfunction (ED) applies to patients with localised prostate cancer. We included 1,282 patients who underwent brachytherapy. ED was classified before treatment according to the Terminology Criteria for Adverse Event Scale version 3.0. ED was defined as the need for the use of oral pharmacologic or mechanical assistance to have satisfactory sexual function. We found that patients with ED were older (p < .001), more likely to have hypertension (p = .002), statin use (p = .002), diabetes (p < .001) or an IPSS ≥ 8 (p < .001). On univariable logistic regression analysis, an NLR of ≥3 was statistically significantly associated with ED (OR 1.32, p = .029). But on multivariable analysis, the association between elevated NLR and ED was not statistically significant (p = .17). Significant were age (OR 1.12, p < .001), IPSS ≥ 8 (OR 1.50, p = .008), the presence of hypertension, hyperlipidemia and diabetes (OR 2.27, p < .001), and prostate volume (OR 0.99, p = .041). The NLR does appear to be a surrogate marker of chronic inflammation that causes baseline ED in patients with localised prostate cancer.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14070Subventions
Organisme : Department of Radiology University of Montreal
Informations de copyright
© 2021 Wiley-VCH GmbH.
Références
Buckstein, M., Carpenter, T. J., Stone, N. N., & Stock, R. G. (2013). Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up. Urology, 81(2), 364-369. https://doi.org/10.1016/j.urology.2012.08.112
De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., & Nelson, W. G. (2007). Inflammation in prostate carcinogenesis. Nature Reviews Cancer, 7(4), 256-269. https://doi.org/10.1038/nrc2090
Demirci, A., & Ozgur, B. C. (2019). The effect of using tadalafil 5 mg/day on neutrophil-lymphocyte and platelet-lymphocyte ratios in mild-medium and severe erectile dysfunction patients; and comparison of clinical response. Andrologia, 51(9), e13347. https://doi.org/10.1111/and.13347
Ficarra, V., Rossanese, M., Zazzara, M., Giannarini, G., Abbinante, M., Bartoletti, R., Mirone, V., & Scaglione, F. (2014). The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Current Urology Reports, 15(12), 463. https://doi.org/10.1007/s11934-014-0463-9
Gaither, T. W., Awad, M. A., Osterberg, E. C., Murphy, G. P., Allen, I. E., Chang, A., Rosen, R. C., & Breyer, B. N. (2017). The natural history of erectile dysfunction after prostatic radiotherapy: A systematic review and meta-analysis. The Journal of Sexual Medicine, 14(9), 1071-1078. https://doi.org/10.1016/j.jsxm.2017.07.010
Geerkens, M. J., Al-Itejawi, H. H., Nieuwenhuijzen, J. A., Meuleman, E. J., Lissenberg-Witte, B. I., van Moorselaar, R., & Vis, A. N. (2020). Sexual dysfunction and bother due to erectile dysfunction in the healthy elderly male population: prevalence from a systematic review. European Urology Focus, 6(4), 776-790. https://doi.org/10.1016/j.euf.2019.03.004
Lloyd, G. L., Marks, J. M., & Ricke, W. A. (2019). Benign prostatic hyperplasia and lower urinary tract symptoms: What is the role and significance of inflammation? Current Urology Reports, 20(9), 54. https://doi.org/10.1007/s11934-019-0917-1
Lloyd, G. L., Ricke, W. A., & McVary, K. T. (2019). Inflammation, voiding and benign prostatic hyperplasia progression. Journal of Urology, 201(5), 868-870.
Nguyen, D. P., Li, J., & Tewari, A. K. (2014). Inflammation and prostate cancer: The role of interleukin 6 (IL-6). BJU International, 113(6), 986-992. https://doi.org/10.1111/bju.12452
Ozer, K., Horsanali, M. O., Gorgel, S. N., Horsanali, B. O., & Ozbek, E. (2017). Association between benign prostatic hyperplasia and neutrophil-lymphocyte ratio, an indicator of inflammation and metabolic syndrome. Urologia Internationalis, 98(4), 466-471. https://doi.org/10.1159/000448289
Sambel, M., Kilic, M., Demirbas, M., Onen, E., Oner, S., Erdogan, A., & Aydos, M. M. (2018). Relationship between erectile dysfunction and the neutrophil to lymphocyte and platelet to lymphocyte ratios. International Journal of Impotence Research, 30(1), 27-35. https://doi.org/10.1038/s41443-017-0007-1
Sanda, M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T. K., Litwin, M. S., Saigal, C. S., Mahadevan, A., Klein, E., Kibel, A., Pisters, L. L., Kuban, D., Kaplan, I., Wood, D., Ciezki, J., Shah, N., & Wei, J. T. (2008). Quality of life and satisfaction with outcome among prostate-cancer survivors. The New England Journal of Medicine, 358, 1250-1261. https://doi.org/10.1056/NEJMoa074311
Stock, R. G., Klein, T. J., Cesaretti, J. A., & Stone, N. N. (2009). Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. International Journal of Radiation Oncology*biology*physics, 74(3), 753-758. https://doi.org/10.1016/j.ijrobp.2008.08.049
Tang, L. U., Li, X., Wang, B., Luo, G., Gu, L., Chen, L., Liu, K., Gao, Y. U., & Zhang, X. U. (2016). Prognostic value of neutrophil-to-lymphocyte ratio in localized and advanced prostate cancer: A systematic review and meta-analysis. PLoS One, 11(4), e0153981. https://doi.org/10.1371/journal.pone.0153981
Tanik, S., Albayrak, S., Zengin, K., Borekci, H., Bakirtas, H., Imamoglu, M. A., & Gurdal, M. (2014). Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia. Asian Pacific Journal of Cancer Prevention, 15(15), 6375-6379. https://doi.org/10.7314/APJCP.2014.15.15.6375
Ventimiglia, E., Cazzaniga, W., Pederzoli, F., Frego, N., Chierigo, F., Capogrosso, P., Boeri, L., Dehò, F., Abbate, C., Moretti, D., Piemonti, L., Montorsi, F., & Salonia, A. (2018). The role of neutrophil-to-lymphocyte ratio in men with erectile dysfunction-preliminary findings of a real-life cross-sectional study. Andrology, 6(4), 559-563. https://doi.org/10.1111/andr.12489
Vlachopoulos, C., Rokkas, K., Ioakeimidis, N., & Stefanadis, C. (2007). Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: Common links. European Urology, 52(6), 1590-1600. https://doi.org/10.1016/j.eururo.2007.08.004
Zagar, T. M., Stock, R. G., Cesaretti, J. A., & Stone, N. N. (2007). Assessment of postbrachytherapy sexual function: A comparison of the IIEF-5 and the MSEFS. Brachytherapy, 6(1), 26-33. https://doi.org/10.1016/j.brachy.2006.11.003
Zhao, H., & Kim, H. H. (2019). The complex relationship between lower urinary tract symptoms and sexual health. Current Urology Reports, 20(10), 58. https://doi.org/10.1007/s11934-019-0930-4